Definition
Polyendocrine metabolic ovarian syndrome (PMOS) - Previously known as Polycystic Ovary Syndrome (PCOS) - is a common, chronic endocrine and metabolic disorder characterised by hyperandrogenism, ovulatory dysfunction and abnormal ovarian follicular development.
It affects approximately 10โ13% of reproductive-aged women.
The condition is associated with:
Excess androgen production.
Insulin resistance and compensatory hyperinsulinaemia.
Irregular or absent ovulation.
Subfertility.
Increased metabolic and cardiovascular risk.
The term PCOS was changed to PMOS in May 2026 following an international consensus process. The new terminology reflects the multisystem nature of the condition rather than focusing on ovarian cysts.
๐น PMOS is a multisystem endocrine and metabolic disorder; ovarian cysts are not required for diagnosis.
Risk Factors
Genetic Factors
First-degree relative with PMOS.
Family history of type 2 diabetes.
Genetic predisposition to insulin resistance.
Metabolic Factors
Obesity, particularly central adiposity.
Insulin resistance.
Family history of metabolic syndrome.
Associated Factors
Previous gestational diabetes.
Sedentary lifestyle.
Sleep disturbance, including obstructive sleep apnoea.
๐น PMOS has a strong genetic component and is frequently associated with insulin resistance.
Classification
Rotterdam Phenotypes
PMOS can present with different combinations of clinical features.
Phenotype A โ Classic
Hyperandrogenism.
Ovulatory dysfunction.
Polycystic ovarian morphology.
Phenotype B
Hyperandrogenism.
Ovulatory dysfunction.
No polycystic ovarian morphology.
Phenotype C โ Ovulatory
Hyperandrogenism.
Polycystic ovarian morphology.
Regular ovulation.
Phenotype D โ Non-Hyperandrogenic
Ovulatory dysfunction.
Polycystic ovarian morphology.
No hyperandrogenism.
๐น All four phenotypes meet the adult Rotterdam diagnostic criteria.
Pathophysiology
Insulin Resistance
Reduced insulin sensitivity in peripheral tissues.
Compensatory hyperinsulinaemia.
Insulin stimulates ovarian theca cells to produce androgens.
Reduced hepatic sex hormone-binding globulin (SHBG).
Hyperandrogenism
Increased ovarian androgen production.
Increased free testosterone due to reduced SHBG.
Causes hirsutism, acne and androgenic alopecia.
Ovulatory Dysfunction
Increased GnRH pulse frequency.
Increased LH relative to FSH in some patients.
Abnormal follicular development.
Failure of regular ovulation.
Oligomenorrhoea or amenorrhoea.
Metabolic Dysfunction
Increased risk of impaired glucose tolerance.
Increased risk of type 2 diabetes.
Dyslipidaemia.
Increased cardiovascular risk.
๐น Insulin resistance โ hyperinsulinaemia โ increased ovarian androgen production โ anovulation.
Clinical Presentation
Menstrual Symptoms
Oligomenorrhoea (infrequent periods).
Amenorrhoea.
Irregular menstrual cycles.
Anovulation.
Subfertility.
Hyperandrogenic Symptoms
Hirsutism
Excess terminal hair growth.
Face, chin, chest, abdomen and back.
Most characteristic clinical feature of hyperandrogenism.
Acne
Persistent or treatment-resistant acne.
Often affects the face, chest and back.
Androgenic Alopecia
Female-pattern hair loss.
Widening of the central parting.
Thinning over the crown.
Metabolic Features
Weight gain, particularly central adiposity.
Difficulty losing weight.
Acanthosis nigricans.
Increased waist circumference.
Associated Symptoms
Reduced fertility.
Anxiety and depression.
Sleep disturbance.
Obstructive sleep apnoea.
Red Flag Features
Rapid onset of hirsutism.
Rapidly progressive virilisation.
Deepening of the voice.
Clitoromegaly.
Rapidly increasing muscle mass.
These suggest an alternative cause of androgen excess, particularly an androgen-secreting ovarian or adrenal tumour.
๐น Irregular periods + hirsutism + acne are characteristic features of PMOS.
Examination Findings
Signs of Hyperandrogenism
Hirsutism (assess using modified FerrimanโGallwey score).
Acne.
Female-pattern hair loss.
Metabolic Findings
Increased BMI or waist circumference.
Acanthosis nigricans โ velvety hyperpigmentation, particularly around the neck and axillae.
Features of insulin resistance.
Gynaecological Examination
May be entirely normal.
Ovarian enlargement is not required.
No specific pelvic examination finding confirms PMOS.
๐น Acanthosis nigricans is a clinical marker of insulin resistance.
Diagnosis
Rotterdam Diagnostic Criteria (Adults)
Diagnosis requires at least 2 of the following 3 criteria, after excluding other causes:
1. Ovulatory Dysfunction
Oligomenorrhoea.
Amenorrhoea.
Anovulation.
2. Clinical or Biochemical Hyperandrogenism
Clinical:
Hirsutism.
Acne or androgenic alopecia may support the diagnosis.
Biochemical:
- Raised total or free testosterone.
3. Polycystic Ovarian Morphology (PCOM)
Identified on pelvic ultrasound.
Alternatively, raised anti-Mรผllerian hormone (AMH) can be used in adults.
Important Diagnostic Rule
If an adult has both:
Irregular menstrual cycles.
Clinical or biochemical hyperandrogenism.
Ultrasound and AMH are NOT required for diagnosis.
Adolescents
Diagnosis requires BOTH:
Ovulatory dysfunction.
Clinical or biochemical hyperandrogenism.
Important:
Ultrasound is not recommended for diagnosis in adolescents.
AMH should not be used for diagnosis in adolescents.
Avoid diagnosing PMOS based on normal pubertal changes alone.
๐น Adults require 2 of 3 Rotterdam criteria; adolescents require both hyperandrogenism and ovulatory dysfunction.
Investigations
Hormonal Blood Tests
Total Testosterone
First-line biochemical assessment of androgen excess.
Usually elevated in PMOS.
Free Testosterone / Free Androgen Index (FAI)
Helps assess androgen excess.
SHBG is often reduced due to insulin resistance.
DHEAS
Helps assess adrenal androgen production.
Markedly elevated levels may suggest an adrenal tumour.
Androstenedione
May be elevated.
Consider if testosterone is normal but clinical suspicion remains.
Exclude Other Causes
Thyroid Function Tests (TFTs)
- Exclude thyroid dysfunction.
Prolactin
- Exclude hyperprolactinaemia.
17-Hydroxyprogesterone
- Exclude non-classical congenital adrenal hyperplasia.
Pregnancy Test
- If amenorrhoea and pregnancy is possible.
FSH
- Consider if premature ovarian insufficiency or ovarian dysfunction is suspected.
Metabolic Assessment
75 g Oral Glucose Tolerance Test (OGTT)
Most accurate test for assessing glycaemic status.
Recommended regardless of BMI.
Identifies impaired glucose tolerance and type 2 diabetes.
Lipid Profile
- Assess total cholesterol, LDL, HDL and triglycerides.
Blood Pressure
- Measure at diagnosis and at least annually.
๐น OGTT is the most accurate test for assessing dysglycaemia in PMOS, regardless of BMI.
Ultrasound Findings
Pelvic Ultrasound
Transvaginal ultrasound preferred in adults where appropriate.
Increased number of small ovarian follicles.
Increased ovarian volume (โฅ10 mL in at least one ovary).
Modern ultrasound criteria: โฅ20 follicles in at least one ovary when using appropriate high-resolution imaging.
Important
These are immature follicles, not true ovarian cysts.
Ultrasound is not required if irregular cycles and hyperandrogenism are already present.
AMH may be used as an alternative to ultrasound in adults, but not as a standalone diagnostic test.
๐น PMOS does not require polycystic ovarian morphology on ultrasound.
Differential Diagnosis
Non-Classical Congenital Adrenal Hyperplasia
Hirsutism.
Irregular periods.
Raised 17-hydroxyprogesterone.
Cushing Syndrome
Central obesity.
Purple striae.
Proximal muscle weakness.
Hypertension.
Elevated cortisol.
Hyperprolactinaemia
Amenorrhoea.
Galactorrhoea.
Reduced libido.
Raised prolactin.
Thyroid Dysfunction
Menstrual irregularities.
Weight changes.
Fatigue.
Abnormal TSH.
Androgen-Secreting Tumour
Rapid onset hirsutism.
Virilisation.
Markedly elevated testosterone or DHEAS.
๐น Rapid virilisation is not typical of PMOS and requires investigation for an androgen-secreting tumour.
Management
Treatment depends on the main clinical problem:
Irregular menstrual cycles.
Hyperandrogenism.
Metabolic dysfunction.
Subfertility.
Lifestyle Management
First-line for all patients, regardless of BMI.
Regular physical activity.
Balanced diet.
Behavioural support.
Weight management where appropriate.
Sleep optimisation.
For patients with higher weight, modest weight reduction can improve:
Insulin sensitivity.
Menstrual regularity.
Ovulation.
Metabolic risk.
๐น Lifestyle intervention is recommended for all patients and can improve metabolic and reproductive outcomes.
Management of Menstrual Irregularities
Combined Oral Contraceptive Pill (COCP)
First-line pharmacological option when pregnancy is not desired.
Regulates menstrual cycles.
Reduces ovarian androgen production.
Increases SHBG.
Reduces free testosterone.
Improves acne and hirsutism.
Progestogen Therapy
Consider when COCP is unsuitable.
Options:
Cyclical oral progestogen.
Progestogen-only contraception.
Levonorgestrel intrauterine system (LNG-IUS).
Purpose:
Provides endometrial protection.
Reduces the risk of endometrial hyperplasia from prolonged anovulation.
๐น COCP regulates periods and improves hyperandrogenic symptoms; progestogen protects the endometrium.
Management of Insulin Resistance
Metformin
Improves insulin sensitivity.
Reduces hepatic glucose production.
May improve menstrual regularity.
May improve metabolic parameters.
Consider particularly in patients with:
BMI โฅ25 kg/mยฒ.
Impaired glucose tolerance.
Increased metabolic risk.
Important:
Does not replace lifestyle intervention.
Gastrointestinal adverse effects are common.
Start at a low dose and increase gradually.
Monitor renal function.
๐น Metformin is primarily used for metabolic features of PMOS rather than as first-line treatment for hirsutism.
Management of Hyperandrogenism
Combined Oral Contraceptive Pill
First-line pharmacological treatment for hirsutism when contraception is acceptable.
Reduces circulating free androgens.
Anti-Androgens
Spironolactone
Blocks androgen receptors.
Reduces hirsutism.
Consider if symptoms persist despite at least 6 months of COCP and cosmetic treatment.
Effective contraception is essential due to potential risk to male fetal genital development.
Monitor potassium and renal function.
๐น Spironolactone may be added for persistent hirsutism, but reliable contraception is essential.
Management of Subfertility
First-Line Treatment
Letrozole
Aromatase inhibitor.
Reduces oestrogen production.
Increases FSH secretion.
Stimulates follicular development and ovulation.
First-line pharmacological ovulation induction in anovulatory infertility when no other infertility factors are present.
Alternative Treatments
Clomifene Citrate
Selective oestrogen receptor modulator (SERM).
Increases pituitary FSH and LH secretion.
Stimulates ovulation.
Alternative if letrozole is unavailable or unsuitable.
Metformin
Improves insulin sensitivity.
May improve ovulation.
Can be used alone or alongside other fertility treatments in selected patients.
Second-Line Treatment
Gonadotrophins
Used when oral ovulation induction is unsuccessful.
Requires ultrasound monitoring due to risk of multiple pregnancy and ovarian hyperstimulation.
Surgical Treatment
Laparoscopic Ovarian Drilling
Consider in selected patients with anovulatory infertility resistant to pharmacological treatment.
Reduces ovarian androgen-producing tissue.
Can restore ovulation.
IVF
- Consider if other fertility treatments are unsuccessful or additional infertility factors exist.
๐น Letrozole is the first-line pharmacological treatment for anovulatory infertility associated with PMOS.
Complications
Reproductive Complications
Anovulatory infertility.
Miscarriage risk.
Gestational diabetes.
Hypertensive disorders of pregnancy.
Pre-eclampsia.
Metabolic Complications
Insulin resistance.
Impaired glucose tolerance.
Type 2 diabetes mellitus.
Dyslipidaemia.
Hypertension.
Increased cardiovascular risk.
Metabolic dysfunction-associated steatotic liver disease (MASLD).
Gynaecological Complications
Endometrial Hyperplasia and Cancer
Chronic anovulation โ reduced progesterone exposure.
Unopposed oestrogen stimulates endometrial proliferation.
Increased risk of endometrial hyperplasia and endometrial cancer.
Prevention:
Weight management.
Regulation of menstrual cycles.
Regular progestogen therapy.
Routine endometrial cancer screening is not recommended.
Psychological Complications
Depression.
Anxiety.
Reduced quality of life.
Body image difficulties.
๐น Chronic anovulation and unopposed oestrogen increase the risk of endometrial hyperplasia.
Follow-Up & Monitoring
Metabolic Monitoring
Blood pressure at least annually.
Lipid profile at diagnosis.
Glycaemic assessment at diagnosis.
Repeat glycaemic assessment every 1โ3 years depending on individual risk.
Additional Monitoring
Monitor menstrual frequency and endometrial protection.
Review weight and metabolic risk factors.
Assess for depression and anxiety.
Screen for symptoms of obstructive sleep apnoea.
๐น PMOS requires long-term metabolic monitoring, even in patients without obesity.
Prognosis
Chronic condition that may persist throughout reproductive life.
Symptoms vary between individuals.
Menstrual and androgenic symptoms can be controlled with treatment.
Fertility is often achievable with appropriate ovulation induction.
Long-term metabolic risks require ongoing monitoring.
๐น PMOS is a lifelong endocrine and metabolic condition, not simply a reproductive disorder.
UKMLA Key Points
PMOS = chronic endocrine and metabolic disorder, previously called PCOS.
New terminology introduced May 2026.
Diagnostic criteria remain unchanged.
Diagnosis in adults = 2 of 3 Rotterdam criteria.
Rotterdam criteria = hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology.
Irregular periods + hyperandrogenism = no ultrasound required.
Adolescents require BOTH hyperandrogenism and ovulatory dysfunction.
Common hormonal finding = raised testosterone and reduced SHBG.
Insulin resistance โ hyperinsulinaemia โ increased ovarian androgen production.
Exclude thyroid dysfunction, hyperprolactinaemia and congenital adrenal hyperplasia.
Most accurate metabolic test = 75 g OGTT.
First-line for menstrual irregularity and hirsutism = COCP.
Metformin = metabolic dysfunction and insulin resistance.
Letrozole = first-line ovulation induction.
Spironolactone = persistent hirsutism; effective contraception required.
Chronic anovulation increases endometrial hyperplasia risk.
Long-term risks = type 2 diabetes, hypertension and dyslipidaemia.
No routine screening for endometrial cancer.
๐น Irregular periods + hirsutism + insulin resistance = suspect PMOS. Remember Rotterdam criteria and the importance of metabolic screening.
References & Guidelines
1. International Evidence-Based Guideline for PMOS (2023, terminology updated May 2026) โ diagnostic criteria, investigations, metabolic screening, fertility and management. The clinical recommendations remain unchanged following the name change.
2. NHS โ Polyendocrine Metabolic Ovarian Syndrome (PMOS) โ symptoms, diagnosis, treatment and long-term complications.
3. NICE CG156 โ Fertility Problems: Assessment and Treatment โ fertility assessment and treatment options, including ovulation induction.
Terminology note: PMOS replaced PCOS on 12 May 2026. Both terms will coexist during the three-year transition period. The international guideline was updated in June 2026; its next full update is planned for 2028. NICE guidance may continue to use the older terminology during this transition.
